FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048800525> ?p ?o ?g. }

• W3048800525 endingPage "1273" @default.
• W3048800525 startingPage "1265" @default.
• W3048800525 abstract "Abstract Background Many patients with classical Hodgkin lymphoma show increased programmed death-1 ligand expression in Reed–Sternberg cells. We report the final results of a phase II study of nivolumab, an anti-programmed death-1 monoclonal antibody, in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Methods Japanese patients with previously treated classical Hodgkin lymphoma (aged ≥ 20 years) were administered nivolumab (3 mg/kg on Day 1 of 14-day cycles) until progressive disease, an unacceptable adverse event, or another clinically relevant reason. Treatment could continue beyond progressive disease at the investigator’s discretion in selected patients. Results Seventeen patients (median age: 63.0 years) were enrolled. The median follow-up was 38.8 months. One patient with non-Hodgkin lymphoma was excluded from efficacy analyses. The centrally assessed overall response rate in 16 classical Hodgkin lymphoma patients was 87.5% (95% confidence interval = 61.7–98.4%) and the disease control rate was 93.8% (95% confidence interval = 69.8–99.8%). The median (95% confidence interval) duration of response and progression-free survival were 8.5 (2.4–12.6) and 11.7 (1.8–42.3) months, respectively. The 3-year overall survival rate was 80.4% (95% confidence interval = 50.6–93.2%). Nivolumab was continued beyond progressive disease in seven patients; six were alive at the data cut-off. Adverse drug reactions occurred in all 17 patients with grades 3–4 adverse drug reactions in eight patients and no grade 5 adverse drug reactions. Pulmonary toxicities occurred in five patients; four of these occurred ≥17 months after starting nivolumab. Conclusion Nivolumab is effective and tolerable in Japanese relapsed or refractory classical Hodgkin lymphoma patients. Continued monitoring may be necessary to detect late-onset pulmonary toxicities. Clinical trial registration JapicCTI-142755 (Japan Pharmaceutical Information Center)." @default.
• W3048800525 created "2020-08-18" @default.
• W3048800525 creator A5013112899 @default.
• W3048800525 creator A5018968800 @default.
• W3048800525 creator A5036000764 @default.
• W3048800525 creator A5036112859 @default.
• W3048800525 creator A5037105339 @default.
• W3048800525 creator A5047640708 @default.
• W3048800525 creator A5055192416 @default.
• W3048800525 creator A5087363470 @default.
• W3048800525 creator A5091136428 @default.
• W3048800525 date "2020-08-08" @default.
• W3048800525 modified "2023-10-18" @default.
• W3048800525 title "Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma" @default.
• W3048800525 cites W2106294189 @default.
• W3048800525 cites W2125616358 @default.
• W3048800525 cites W2133201432 @default.
• W3048800525 cites W2261336475 @default.
• W3048800525 cites W2264532235 @default.
• W3048800525 cites W2337325750 @default.
• W3048800525 cites W2337659275 @default.
• W3048800525 cites W2504623699 @default.
• W3048800525 cites W2523986803 @default.
• W3048800525 cites W2552995821 @default.
• W3048800525 cites W2591641966 @default.
• W3048800525 cites W2609973112 @default.
• W3048800525 cites W2725298133 @default.
• W3048800525 cites W2775803967 @default.
• W3048800525 cites W2784235889 @default.
• W3048800525 cites W2786224778 @default.
• W3048800525 cites W2794872274 @default.
• W3048800525 cites W2889646458 @default.
• W3048800525 cites W2894928555 @default.
• W3048800525 cites W2896600370 @default.
• W3048800525 cites W2924161074 @default.
• W3048800525 cites W2968942240 @default.
• W3048800525 cites W4245503015 @default.
• W3048800525 doi "https://doi.org/10.1093/jjco/hyaa117" @default.
• W3048800525 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7579338" @default.
• W3048800525 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32776097" @default.
• W3048800525 hasPublicationYear "2020" @default.
• W3048800525 type Work @default.
• W3048800525 sameAs 3048800525 @default.
• W3048800525 citedByCount "11" @default.
• W3048800525 countsByYear W30488005252021 @default.
• W3048800525 countsByYear W30488005252022 @default.
• W3048800525 countsByYear W30488005252023 @default.
• W3048800525 crossrefType "journal-article" @default.
• W3048800525 hasAuthorship W3048800525A5013112899 @default.
• W3048800525 hasAuthorship W3048800525A5018968800 @default.
• W3048800525 hasAuthorship W3048800525A5036000764 @default.
• W3048800525 hasAuthorship W3048800525A5036112859 @default.
• W3048800525 hasAuthorship W3048800525A5037105339 @default.
• W3048800525 hasAuthorship W3048800525A5047640708 @default.
• W3048800525 hasAuthorship W3048800525A5055192416 @default.
• W3048800525 hasAuthorship W3048800525A5087363470 @default.
• W3048800525 hasAuthorship W3048800525A5091136428 @default.
• W3048800525 hasBestOaLocation W30488005251 @default.
• W3048800525 hasConcept C121332964 @default.
• W3048800525 hasConcept C121608353 @default.
• W3048800525 hasConcept C126322002 @default.
• W3048800525 hasConcept C141071460 @default.
• W3048800525 hasConcept C142424586 @default.
• W3048800525 hasConcept C197934379 @default.
• W3048800525 hasConcept C2776694085 @default.
• W3048800525 hasConcept C2777701055 @default.
• W3048800525 hasConcept C2778822529 @default.
• W3048800525 hasConcept C2779338263 @default.
• W3048800525 hasConcept C2780030458 @default.
• W3048800525 hasConcept C44249647 @default.
• W3048800525 hasConcept C71924100 @default.
• W3048800525 hasConcept C87355193 @default.
• W3048800525 hasConcept C90924648 @default.
• W3048800525 hasConceptScore W3048800525C121332964 @default.
• W3048800525 hasConceptScore W3048800525C121608353 @default.
• W3048800525 hasConceptScore W3048800525C126322002 @default.
• W3048800525 hasConceptScore W3048800525C141071460 @default.
• W3048800525 hasConceptScore W3048800525C142424586 @default.
• W3048800525 hasConceptScore W3048800525C197934379 @default.
• W3048800525 hasConceptScore W3048800525C2776694085 @default.
• W3048800525 hasConceptScore W3048800525C2777701055 @default.
• W3048800525 hasConceptScore W3048800525C2778822529 @default.
• W3048800525 hasConceptScore W3048800525C2779338263 @default.
• W3048800525 hasConceptScore W3048800525C2780030458 @default.
• W3048800525 hasConceptScore W3048800525C44249647 @default.
• W3048800525 hasConceptScore W3048800525C71924100 @default.
• W3048800525 hasConceptScore W3048800525C87355193 @default.
• W3048800525 hasConceptScore W3048800525C90924648 @default.
• W3048800525 hasFunder F4320327845 @default.
• W3048800525 hasIssue "11" @default.
• W3048800525 hasLocation W30488005251 @default.
• W3048800525 hasLocation W30488005252 @default.
• W3048800525 hasLocation W30488005253 @default.
• W3048800525 hasOpenAccess W3048800525 @default.
• W3048800525 hasPrimaryLocation W30488005251 @default.
• W3048800525 hasRelatedWork W2003938723 @default.
• W3048800525 hasRelatedWork W2047967234 @default.
• W3048800525 hasRelatedWork W2118496982 @default.

• next